FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2019465287> ?p ?o ?g. }

• W2019465287 endingPage "396" @default.
• W2019465287 startingPage "389" @default.
• W2019465287 abstract "PEG Intron (pegylated interferon-alpha-2b [IFN-alpha-2b]; Schering-Plough, Kenilworth, NJ) has demonstrated delayed clearance and increased area under the curve compared with native IFN-alpha-2b. Studies in patients with chronic hepatitis C infection and malignancies have demonstrated both biologic and clinical activity of PEG Intron and have provided empiric data to compare the pharmacokinetics (PK) and pharmacodynamics of PEG Intron and IFN-alpha-2b.The authors conducted a review of the available data comparing the PK and pharmacodynamic effects of PEG Intron and IFN-alpha-2b. Safety and efficacy data from Phase I/II studies of PEG Intron in patients with chronic myelogenous leukemia (CML) and solid tumors were also reviewed.Data from patients with chronic hepatitis C infection suggest that exposure to IFN at a PEG Intron dose of 0.25 microg/kg per week is similar to that observed after administration of IFN-alpha-2b at a dose of 3 million International Units, three times per week. PEG Intron at doses up to 6 microg/kg per week was well tolerated and demonstrated clinical activity in patients with CML and solid tumors, including metastatic melanoma and renal cell carcinoma.Dose intensification can be achieved safely in patients with CML and solid tumors using PEG Intron, which could improve efficacy. These results provide useful dosing guidelines to clinicians investigating the antitumor activity of PEG Intron in patients with malignancies. More data are needed to determine the optimal dose in various oncologic indications. However, these results provide a sound rationale for further investigation of PEG Intron." @default.
• W2019465287 created "2016-06-24" @default.
• W2019465287 creator A5000735749 @default.
• W2019465287 creator A5004071908 @default.
• W2019465287 creator A5004577239 @default.
• W2019465287 creator A5005738281 @default.
• W2019465287 creator A5018504473 @default.
• W2019465287 creator A5082466279 @default.
• W2019465287 date "2002-07-11" @default.
• W2019465287 modified "2023-10-16" @default.
• W2019465287 title "Treating cancer with PEG Intron" @default.
• W2019465287 cites W1475192479 @default.
• W2019465287 cites W1498708301 @default.
• W2019465287 cites W1982188484 @default.
• W2019465287 cites W1985269587 @default.
• W2019465287 cites W2016479172 @default.
• W2019465287 cites W2022243496 @default.
• W2019465287 cites W2065225927 @default.
• W2019465287 cites W2098896033 @default.
• W2019465287 cites W2122797075 @default.
• W2019465287 cites W2142337801 @default.
• W2019465287 cites W2153732953 @default.
• W2019465287 cites W2156574153 @default.
• W2019465287 cites W2337277825 @default.
• W2019465287 doi "https://doi.org/10.1002/cncr.10663" @default.
• W2019465287 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12124839" @default.
• W2019465287 hasPublicationYear "2002" @default.
• W2019465287 type Work @default.
• W2019465287 sameAs 2019465287 @default.
• W2019465287 citedByCount "145" @default.
• W2019465287 countsByYear W20194652872012 @default.
• W2019465287 countsByYear W20194652872013 @default.
• W2019465287 countsByYear W20194652872014 @default.
• W2019465287 countsByYear W20194652872015 @default.
• W2019465287 countsByYear W20194652872016 @default.
• W2019465287 countsByYear W20194652872017 @default.
• W2019465287 countsByYear W20194652872018 @default.
• W2019465287 countsByYear W20194652872019 @default.
• W2019465287 countsByYear W20194652872020 @default.
• W2019465287 countsByYear W20194652872021 @default.
• W2019465287 countsByYear W20194652872022 @default.
• W2019465287 crossrefType "journal-article" @default.
• W2019465287 hasAuthorship W2019465287A5000735749 @default.
• W2019465287 hasAuthorship W2019465287A5004071908 @default.
• W2019465287 hasAuthorship W2019465287A5004577239 @default.
• W2019465287 hasAuthorship W2019465287A5005738281 @default.
• W2019465287 hasAuthorship W2019465287A5018504473 @default.
• W2019465287 hasAuthorship W2019465287A5082466279 @default.
• W2019465287 hasBestOaLocation W20194652871 @default.
• W2019465287 hasConcept C10138342 @default.
• W2019465287 hasConcept C104317684 @default.
• W2019465287 hasConcept C111113717 @default.
• W2019465287 hasConcept C112705442 @default.
• W2019465287 hasConcept C121608353 @default.
• W2019465287 hasConcept C126322002 @default.
• W2019465287 hasConcept C143998085 @default.
• W2019465287 hasConcept C162324750 @default.
• W2019465287 hasConcept C203014093 @default.
• W2019465287 hasConcept C2776178377 @default.
• W2019465287 hasConcept C2776960273 @default.
• W2019465287 hasConcept C2778461978 @default.
• W2019465287 hasConcept C2909179924 @default.
• W2019465287 hasConcept C54400483 @default.
• W2019465287 hasConcept C55493867 @default.
• W2019465287 hasConcept C71924100 @default.
• W2019465287 hasConcept C86803240 @default.
• W2019465287 hasConcept C90924648 @default.
• W2019465287 hasConcept C94671646 @default.
• W2019465287 hasConcept C98274493 @default.
• W2019465287 hasConceptScore W2019465287C10138342 @default.
• W2019465287 hasConceptScore W2019465287C104317684 @default.
• W2019465287 hasConceptScore W2019465287C111113717 @default.
• W2019465287 hasConceptScore W2019465287C112705442 @default.
• W2019465287 hasConceptScore W2019465287C121608353 @default.
• W2019465287 hasConceptScore W2019465287C126322002 @default.
• W2019465287 hasConceptScore W2019465287C143998085 @default.
• W2019465287 hasConceptScore W2019465287C162324750 @default.
• W2019465287 hasConceptScore W2019465287C203014093 @default.
• W2019465287 hasConceptScore W2019465287C2776178377 @default.
• W2019465287 hasConceptScore W2019465287C2776960273 @default.
• W2019465287 hasConceptScore W2019465287C2778461978 @default.
• W2019465287 hasConceptScore W2019465287C2909179924 @default.
• W2019465287 hasConceptScore W2019465287C54400483 @default.
• W2019465287 hasConceptScore W2019465287C55493867 @default.
• W2019465287 hasConceptScore W2019465287C71924100 @default.
• W2019465287 hasConceptScore W2019465287C86803240 @default.
• W2019465287 hasConceptScore W2019465287C90924648 @default.
• W2019465287 hasConceptScore W2019465287C94671646 @default.
• W2019465287 hasConceptScore W2019465287C98274493 @default.
• W2019465287 hasIssue "2" @default.
• W2019465287 hasLocation W20194652871 @default.
• W2019465287 hasLocation W20194652872 @default.
• W2019465287 hasOpenAccess W2019465287 @default.
• W2019465287 hasPrimaryLocation W20194652871 @default.
• W2019465287 hasRelatedWork W1786566242 @default.
• W2019465287 hasRelatedWork W2046677216 @default.
• W2019465287 hasRelatedWork W2072863028 @default.
• W2019465287 hasRelatedWork W2085391226 @default.

• next